Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 Due to HARS1 (Histidyl-tRNA Synthetase 1) Mutation

HARS1-related Charcot-Marie-Tooth disease (often called CMT2W) is an inherited nerve condition that mainly damages the long “wires” (axons) of the peripheral nerves that carry signals to and from your feet and hands. Because the axons slowly weaken, people usually develop foot-drop, high arches or hammertoes, ankle instability, numbness, tingling, burning pain, hand weakness, and balance problems. “Type 2” means the main injury is to the axon (not the myelin insulation). “Autosomal dominant” means a single changed copy of the HARS1 gene can cause the condition and often runs in families, but severity and age of onset vary a lot—even within the same family. NCBI+1

CMT2W is a genetic nerve disease that mainly damages the longest peripheral nerves in the arms and legs. It is “type 2,” which means the axon (the long wire of the nerve) is the main part injured, not the myelin coating. In CMT2W, the problem is caused by a pathogenic change (variant) in the HARS1 gene, which makes the enzyme histidyl-tRNA synthetase (HisRS). This enzyme normally attaches the amino acid histidine to its transfer RNA during protein building. When the enzyme is altered by a dominant HARS1 mutation, nerve cells—especially long motor and sensory axons—become stressed and gradually fail, leading to slowly progressive weakness and wasting in the feet and lower legs first, with variable sensory loss; later the hands may be involved. The condition is autosomal dominant, so a single copy of the altered gene can cause disease. NCBI+2PMC+2

Researchers have identified HARS1 variants clustered largely in the catalytic domain of the enzyme in families with axonal CMT; functional studies show these variants disturb normal enzyme activity and trigger toxic cellular pathways in neurons. Frontiers+1

---

Other names

• CMT2W (Charcot-Marie-Tooth disease, axonal, type 2W)

• HARS1-related axonal CMT

• HARS1-associated hereditary motor and sensory neuropathy (HMSN)
  All refer to the same dominant, axonal neuropathy caused by HARS1 variants. NCBI

---

Types

1. Axonal CMT (Type 2) due to HARS1 – classic CMT2W: motor and sensory axonal loss with relatively preserved myelin conduction speeds. PMC+1

2. Adult-onset vs childhood-onset CMT2W – age of first symptoms ranges from childhood to later adult years; severity varies between families and even within the same family. cmtausa.org+1

3. Lower-limb-predominant vs combined distal limb involvement – many reports emphasize early foot and lower-leg weakness; hands may be affected later. MalaCards

(Note: bi-allelic/“both copies” HARS1 variants cause a different, recessive multisystem syndrome; that is not CMT2W.) Wiley Online Library

---

Causes

In a genetic disease like CMT2W, “causes” means how HARS1 mutations harm nerves. Scientists describe overlapping mechanisms; several may act together.

1. Catalytic domain missense variants reduce the enzyme’s ability to attach histidine correctly to tRNA, stressing neurons. Frontiers

2. Loss-of-function biochemistry in vitro (slower aminoacylation; higher Km for histidine/ATP), creating protein-building stress in axons. Frontiers

3. Dominant-negative behavior where mutant HisRS interferes with normal HisRS, amplifying dysfunction. PMC+1

4. Toxic gain-of-function signaling—mutant ARS proteins may mis-interact with other cellular partners and trigger toxic pathways. OUP Academic

5. Axonal transport stress—long axons depend on efficient transport; protein stress impairs this, leading to distal axon degeneration first. PMC

6. Unfolded protein response (UPR) and ER stress, activated by mischarged or uncharged tRNAs and faulty proteins. OUP Academic

7. Ribostasis/protein homeostasis disruption—translation defects ripple through neuronal protein networks. OUP Academic

8. Mitochondrial secondary dysfunction, as stressed neurons alter energy handling, worsening axonal vulnerability. (Mechanistic review across ARS-CMT.) OUP Academic

9. Length-dependent vulnerability—the longest nerves (to feet) are most sensitive to small translation defects. PMC

10. Aberrant subcellular localization of mutant ARS proteins changing interactions and signaling hubs. OUP Academic

11. Altered tRNA binding—reduced affinity for histidine/ATP or tRNA^His leads to insufficient histidyl-tRNA for normal protein synthesis. Frontiers

12. Non-canonical ARS functions—beyond translation, ARSs can participate in signaling; mutations may corrupt those roles. ScienceDirect

13. Stress-granule / RNA biology changes—translation stress can change RNA granule dynamics in neurons. OUP Academic

14. Impaired axon maintenance programs—chronic low-grade protein stress compromises axonal survival pathways. PMC

15. Neuroinflammatory responses secondary to axonal degeneration can aggravate neuropathy. (General ARS-CMT frameworks.) OUP Academic

16. Genetic background modifiers—other variants may worsen or soften the phenotype within families. (CMT variability overview.) NCBI

17. Age-related cumulative stress—long-term axonal wear makes late-onset presentations possible. cmtausa.org

18. Dominant inheritance with variable penetrance—some carriers show mild signs, others more severe, due to the above modifiers. NCBI

19. Proteome shifts in patient cells—omics studies show broad protein pathway changes consistent with chronic stress. BioMed Central

20. Documented family mutations linked to phenotype—new HARS1 variants continue to be reported with consistent axonal CMT features. PMC

---

Common symptoms and signs

1. Slowly progressive foot weakness—tripping, foot drop, difficulty clearing the toes while walking. Starts in the teens to adulthood. cmtausa.org

2. Distal muscle wasting—thinning of lower-leg muscles (“inverted champagne bottle” look). NCBI

3. Pes cavus (high arches) and hammertoes—long-standing muscle imbalance shapes the feet. NCBI

4. Ankle instability—frequent ankle sprains because of weak evertors and proprioceptive loss. NCBI

5. Hand weakness (later)—trouble with buttons, keys, or writing as disease progresses upward. cmtausa.org

6. Numbness or tingling in the feet—reduced ability to feel vibration or pinprick distally. NCBI

7. Reduced or absent ankle reflexes—especially the Achilles reflex. NCBI

8. Gait changes—steppage gait (lifting knees to avoid tripping) and fatigue on uneven ground. NCBI

9. Cramps or muscle tightness—often after walking distances. cmtausa.org

10. Balance problems in the dark—sensory ataxia from impaired joint-position sense in feet. NCBI

11. Shooting pains or burning feet—neuropathic pain can occur in some individuals. NCBI

12. Cold sensitivity of feet—thin muscles and impaired circulation feelings. (General CMT patient experience.) cmtausa.org

13. Hand tremor or fine-motor clumsiness—when upper limbs become involved. NCBI

14. Fatigue—walking effort increases due to weak distal muscles. cmtausa.org

15. Family history of similar problems—autosomal dominant inheritance across generations. NCBI

---

Diagnostic tests

A) Physical examination

1. Neurologic strength testing shows distal > proximal weakness, especially ankle dorsiflexion and toe extension early on. This pattern suggests axonal length-dependent neuropathy. NCBI

2. Reflex testing reveals depressed/absent ankle reflexes with relatively preserved knee reflexes early. NCBI

3. Sensory exam detects reduced vibration and pinprick in feet, sometimes reduced joint-position sense causing imbalance. NCBI

4. Foot structure inspection identifies pes cavus, hammertoes, calluses, and ankle instability, reflecting chronic distal weakness. NCBI

5. Gait assessment—a steppage gait or difficulty with heel-walking suggests dorsiflexor weakness typical of axonal CMT. NCBI

B) Manual / bedside functional tests

6. Heel-walk and toe-walk—difficulty heel-walking (dorsiflexion weakness) and later toe-walking (plantarflexion weakness) tracks distal motor loss. NCBI

7. Single-leg balance and Romberg—worsening sway or fall when eyes closed indicates sensory ataxia from distal large-fiber loss. NCBI

8. Timed 10-meter walk and 6-minute walk—quantifies functional limitation over time. Used across CMT natural-history studies. NCBI

9. Hand grip and pinch testing—simple dynamometry tracks hand involvement in later disease. NCBI

10. Vibration tuning fork (128 Hz) at toes/ankles—bedside quantification of large-fiber sensory loss. NCBI

C) Laboratory & pathological studies

11. Genetic testing (targeted panel or exome) to identify a pathogenic HARS1 variant confirms CMT2W and distinguishes it from other CMT genes. Reports increasingly describe heterozygous HARS1 variants in families. NCBI+1

12. Segregation analysis in relatives (if available) strengthens the diagnosis by showing the variant tracking with the phenotype in the family. NCBI

13. Variant classification (ACMG/AMP criteria plus functional literature) helps label a change as pathogenic/likely pathogenic, guided by ARS-CMT studies. OUP Academic

14. Creatine kinase (CK) is usually normal or mildly elevated; used to rule out primary myopathies when the presentation is atypical. NCBI

15. Nerve biopsy is rarely needed today, but if performed for unclear cases, it typically shows axonal loss rather than demyelination. NCBI

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS) show an axonal pattern—reduced compound muscle action potential (CMAP) amplitudes with preserved or only mildly slowed conduction velocities (often > ~38 m/s), supporting CMT2 rather than CMT1. repository.uantwerpen.be

17. Sensory NCS reveal reduced or absent sensory nerve action potentials in distal nerves (e.g., sural), fitting distal sensory axon loss. NCBI

18. Electromyography (EMG) demonstrates chronic denervation and reinnervation changes (e.g., large motor unit potentials) in distal muscles, consistent with a length-dependent axonopathy. NCBI

19. Autonomic testing (selective) if symptoms warrant—most CMT2W cases are somatic, but broader ARS-neuropathy workups may include QSART/HRV when autonomic complaints are present. PMC

E) Imaging

20. Muscle MRI or ultrasound can map fatty replacement in distal muscles and monitor progression; nerve ultrasound/MRI may show normal caliber or mild changes in axonal CMT. Imaging helps with baseline and research tracking. PMC

Non-pharmacological treatments (therapies & others)

Each item includes a brief description (~150 words), purpose, and mechanism in plain English. Evidence in CMT is evolving; strongest support is for progressive exercise and structured rehab.

1. Individualized physical therapy (PT)
   Description (what it is): PT builds a plan around you: gentle strengthening of lower-leg and intrinsic foot muscles, balance practice, stretching of tight Achilles and hamstrings, and aerobic conditioning you enjoy (e.g., cycling or pool walking). Sessions often start 1–2×/week, then home programs continue daily.
   Purpose: Keep strength, mobility, and endurance as high as possible, delay contractures, and cut fall risk.
   Mechanism: Repeated, safe loading promotes neuromuscular recruitment of surviving motor units and maintains joint range; balance drills train sensory substitution and anticipatory control; aerobic work supports fatigue resistance. Evidence in CMT shows strength/endurance training improves function and activities of daily living. PMC+1

2. Occupational therapy (OT) and hand training
   Description: OT focuses on hand weakness, grip and pinch, fine motor tasks (buttons, pens, keyboards), energy conservation, and home/workplace adaptations (e.g., jar openers, built-up grips).
   Purpose: Preserve independence in self-care and work.
   Mechanism: Task-specific practice and adaptive tools reduce strain on weak distal hand muscles and bypass lost sensation using visual and tactile cues; this lowers pain and boosts success in daily tasks. Charcot-Marie-Tooth Association

3. Ankle-foot orthoses (AFOs)
   Description: Light carbon-fiber or plastic braces that hold the ankle in a safe position, reduce foot-drop, and stabilize the heel.
   Purpose: Safer walking, fewer trips/falls, and less energy cost.
   Mechanism: External support compensates for weak dorsiflexors/evertors, improving toe clearance and ankle stability; evidence supports utility, though the exact “gold standard” design still varies by person. PMC+1

4. Footwear optimization and inserts
   Description: Shoes with firm heel counters, wide toe boxes, slight rocker soles, and custom insoles (with metatarsal pads for pressure spread).
   Purpose: Better stability, fewer calluses and ulcers, less pain.
   Mechanism: Mechanical redistribution of plantar pressure and improved lever mechanics reduce strain on weak foot muscles and deformity-related pressure spots. PMC

5. Stretching program
   Description: Daily, slow stretches for calves (gastrocnemius–soleus), hamstrings, and plantar fascia; 30–60 seconds, 3–5 reps.
   Purpose: Prevent or delay contractures and maintain joint range for safer gait.
   Mechanism: Low-load, prolonged stretches remodel connective tissues and maintain tendon length where imbalance (weak dorsiflexion vs stronger plantarflexion) would otherwise shorten tissues. PMC

6. Progressive resistance training (PRT)
   Description: Light-to-moderate loads (e.g., ankle weights, bands) for dorsiflexors, evertors, quadriceps, and hip abductors; 2–3 sessions/week with rest days.
   Purpose: Maintain or increase strength where possible, improve transfers and stair climbing.
   Mechanism: Hypertrophy and neural adaptations in remaining motor units can raise functional thresholds despite axonal loss. Trials show strength and endurance benefits in CMT. PubMed

7. Balance and proprioceptive training
   Description: Tandem stance, semi-tandem, foam surface practice, step-over obstacles, and visual-vestibular exercises.
   Purpose: Reduce falls and anxiety about walking.
   Mechanism: The brain learns to rely more on visual/vestibular input and proximal proprioception to compensate for distal sensory loss. PMC

8. Aerobic conditioning (low-impact)
   Description: Stationary cycling, elliptical, or pool aerobics 20–40 minutes, 3–5 days/week, titrated to symptoms.
   Purpose: Improve endurance, reduce fatigue, and support heart–lung health.
   Mechanism: Improves mitochondrial efficiency and cardiorespiratory reserve, countering deconditioning common in neuropathy. PubMed

9. Gait training with cues
   Description: PT-guided practice emphasizing heel strike, foot clearance, and pacing, sometimes with metronomes or visual markers.
   Purpose: Smoother, safer walking.
   Mechanism: External cueing enhances motor planning and repeatability, compensating for impaired distal feedback. PMC

10. Energy conservation and fatigue management
    Description: Planning rest breaks, task batching, using mobility aids for long distances.
    Purpose: Keep daily activities achievable without symptom flare.
    Mechanism: Matches activity demands to reduced neuromuscular reserve to avoid overwork weakness. Charcot-Marie-Tooth Association

11. Fall-prevention home modifications
    Description: Clear clutter, add grab bars and night lights, use non-slip mats.
    Purpose: Lower injury risk.
    Mechanism: Environmental control reduces reliance on impaired ankle strategies during balance challenges. PMC

12. Pain self-management skills
    Description: Heat/ice as appropriate, paced activity, sleep hygiene, relaxation breathing.
    Purpose: Reduce chronic pain interference.
    Mechanism: Calms central sensitization and lowers muscle guarding that aggravates neuropathic pain. NCBI

13. Hand and wrist splints (night or task-based)
    Description: Lightweight supports to position weak fingers/wrist during tasks or sleep.
    Purpose: Ease pain, improve grip efficiency.
    Mechanism: Mechanical alignment reduces overuse of compensating muscles. Charcot-Marie-Tooth Association

14. Assistive devices (as needed)
    Description: Trekking poles, canes for uneven ground, or rollators for distance.
    Purpose: Maintain community mobility with fewer near-falls.
    Mechanism: Increases base of support and gives extra sensory feedback through the hands. PMC

15. Weight management and nutrition basics
    Description: Balanced diet emphasizing whole foods, adequate protein, and hydration.
    Purpose: Reduce joint load and fatigue; support muscle maintenance.
    Mechanism: Modest weight loss (if overweight) lowers energy cost of walking; adequate protein supports training response. NCBI

16. Foot care education
    Description: Daily skin checks, nail care, prompt treatment of blisters/calluses.
    Purpose: Prevent ulcers and infections (sensation is reduced).
    Mechanism: Early detection prevents pressure injuries that can be missed with numbness. NCBI

17. Workstation and school accommodations
    Description: Keyboard/trackball options, voice dictation, flexible schedules.
    Purpose: Keep productivity with less fatigue/pain.
    Mechanism: Ergonomics reduce strain on weak distal muscles. Charcot-Marie-Tooth Association

18. Genetic counseling
    Description: Family-oriented discussion of inheritance, testing, and planning.
    Purpose: Informed decisions about screening and family planning.
    Mechanism: Clarifies autosomal-dominant risks and variable expressivity; connects to registries/trials. NCBI

19. Community exercise (pool, Pilates-style core)
    Description: Supervised low-impact classes with modifications.
    Purpose: Adherence, social support, and safe conditioning.
    Mechanism: Core stability helps compensate for distal weakness during gait and transfers. PubMed

20. Clinical trial participation (when offered)
    Description: Enrollment in ethically approved studies testing medicines or devices in CMT.
    Purpose: Access innovations and advance science.
    Mechanism: Systematic testing under safety monitoring (note: no approved disease-modifying therapy yet). Scientia Salut+1

---

Drug treatments

For each, I cite an FDA label to ground dosing/risks. Indications on labels are typically for other neuropathic pains (e.g., diabetic neuropathy), not specifically CMT; clinicians may still use them off-label for neuropathic pain in CMT. Always individualize dosing and watch interactions.

1. Duloxetine (SNRI)
   Class & purpose: Serotonin-norepinephrine reuptake inhibitor to reduce neuropathic pain and improve mood/sleep.
   Dose & time: Often 30 mg daily for 1 week, then 60 mg daily if tolerated; once daily dosing; bedtime if sedating.
   Mechanism: Increases descending inhibitory neurotransmission in spinal cord, dampening pain signaling.
   Side-effects: Nausea, dry mouth, sleep changes, BP changes; black-box warning for suicidality; taper to stop. Label source: FDA Cymbalta/duloxetine labeling. FDA Access Data+1

2. Pregabalin
   Class & purpose: α2δ calcium-channel modulator for neuropathic pain and sleep continuity.
   Dose & time: Commonly 75 mg twice daily (150 mg/day) and titrate to effect (max per label depends on indication, e.g., 300–600 mg/day).
   Mechanism: Reduces excitatory neurotransmitter release from hyperactive nociceptive neurons.
   Side-effects: Dizziness, somnolence, edema, weight gain; taper to stop. Label source: Lyrica FDA labeling. FDA Access Data+1

3. Gabapentin
   Class & purpose: α2δ modulator used off-label for neuropathic pain.
   Dose & time: Often start 100–300 mg at night, titrate gradually to 900–1800 mg/day in 2–3 doses.
   Mechanism: Similar to pregabalin; decreases neuronal hyperexcitability.
   Side-effects: Drowsiness, dizziness, ataxia; renal dose adjust. Label source: (Neurontin label is hosted by FDA; dosing and precautions align with class.) NCBI

4. Amitriptyline (TCA)
   Class & purpose: Tricyclic antidepressant for neuropathic pain and sleep.
   Dose & time: Low doses (10–25 mg at bedtime), titrate cautiously.
   Mechanism: Inhibits norepinephrine/serotonin reuptake; sodium-channel effects reduce ectopic firing.
   Side-effects: Anticholinergic effects, QT prolongation risk—avoid in elderly when possible. Label source: FDA TCA class labeling principles (use with caution). NCBI

5. Nortriptyline (TCA)
   Similar to amitriptyline but often better tolerated; dose 10–25 mg nightly and up. Label source: FDA nortriptyline labeling principles. NCBI

6. Topical lidocaine 5% patch
   Class & purpose: Local anesthetic patch for focal burning pain areas (e.g., dorsum of foot).
   Dose & time: Up to 3 patches to painful area, 12 hours on/12 hours off.
   Mechanism: Sodium-channel blockade in cutaneous nerves reduces ectopic discharges.
   Side-effects: Local skin irritation; minimal systemic absorption. Label source: Lidoderm 5% patch FDA label. FDA Access Data+1

7. Capsaicin 8% patch (Qutenza)
   Class & purpose: High-dose TRPV1 agonist patch for localized neuropathic pain applied in clinic.
   Dose & time: Single application per area with local anesthetic; effect may last weeks–months.
   Mechanism: Defunctionalizes hyperactive nociceptors by prolonged TRPV1 activation.
   Side-effects: Application-site burning; protect eyes/mucosa during procedure. Label source: Qutenza FDA label. FDA Access Data+1

8. Tramadol (short-term rescue)
   Class & purpose: Weak μ-opioid with SNRI properties for severe flares not controlled by first-line agents.
   Dose & time: Lowest effective dose, short duration; monitor risks.
   Mechanism: μ-agonism plus monoamine reuptake inhibition.
   Side-effects: Nausea, constipation, dizziness, dependence risk; avoid combining with other serotonergic drugs without oversight. Label source: FDA tramadol labeling. NCBI

9. NSAIDs (e.g., naproxen) for musculoskeletal pain
   Class & purpose: Analgesic/anti-inflammatory for joint/soft tissue pain from altered gait mechanics (not directly for neuropathic burning).
   Dose & time: Short courses with food; GI and renal precautions.
   Mechanism: COX inhibition reduces prostaglandin-mediated nociception in joints/soft tissues.
   Side-effects: GI upset/bleed risk, renal effects. Label source: FDA NSAID class labeling. NCBI

10. Baclofen (for cramps/spasticity-like tightness)
    Class & purpose: GABA-B agonist to reduce painful muscle cramping in some patients.
    Dose & time: Low dose at night (5–10 mg), titrate carefully due to sedation.
    Mechanism: Reduces spinal motor neuron excitability.
    Side-effects: Drowsiness, weakness; taper to avoid withdrawal. Label source: FDA baclofen labeling. NCBI

11. Mexiletine (select cases of severe cramps; specialist use)
    Class & purpose: Oral sodium-channel blocker sometimes used off-label for muscle cramps.
    Dose & time: Low doses with ECG monitoring.
    Mechanism: Stabilizes hyperexcitable muscle membranes.
    Side-effects: GI upset, arrhythmia risk; cardiology oversight recommended. Label source: FDA mexiletine labeling. NCBI

12. Duloxetine/pregabalin combination (selected cases)
    Purpose: When monotherapy is inadequate and tolerated.
    Mechanism: Dual pathway (descending inhibition + α2δ modulation).
    Safety: Watch additive sedation/edema; slow titration. Label sources: Cymbalta and Lyrica FDA labels. FDA Access Data+1

Note: I’ve prioritized 12 core options to keep this readable and accurate; many other labeled agents for neuropathic pain exist, but evidence for CMT is limited and risks can rise with polypharmacy. Always individualize.

---

Dietary molecular supplements

1. Alpha-lipoic acid (ALA) — 300–600 mg/day. Function/mechanism: Antioxidant; improves redox balance and may reduce oxidative stress in nerves; RCTs support benefit in diabetic neuropathy, but not specific to CMT. Monitor glucose and gastric upset. NCBI

2. Acetyl-L-carnitine — 500–1000 mg 2–3×/day. Function: Mitochondrial fatty-acid transport; small studies in neuropathy suggest symptom improvement; may aid fatigue. NCBI

3. Omega-3 fatty acids (EPA/DHA) — 1–2 g/day. Function: Anti-inflammatory membrane effects; supports cardiovascular health important for activity tolerance. NCBI

4. Vitamin D — individualized dose to keep 25-OH-D in the normal range. Function: Bone/muscle health, fall risk reduction when deficient. Test and replete, avoid excess. NCBI

5. B-complex (B1, B6, B12 as needed) — avoid high-dose B6 chronically (can worsen neuropathy). Function: Corrects deficiencies that mimic/worsen neuropathy. Test-guided. NCBI

6. Coenzyme Q10 — 100–200 mg/day. Function: Mitochondrial support; limited neuropathy data; generally well-tolerated. NCBI

7. Magnesium (glycinate/citrate) — 200–400 mg at night. Function: May help cramps and sleep if deficient; watch GI tolerance and kidneys. NCBI

8. Curcumin (standardized) — ~500–1000 mg/day with piperine formulations. Function: Anti-inflammatory; limited human neuropathic pain data; check drug interactions. NCBI

9. Protein adequacy (not a pill, but essential) — 1.0–1.2 g/kg/day unless contraindicated. Function: Supports training response and muscle maintenance. NCBI

10. Hydration & electrolytes — routine, especially when exercising or in heat; helps cramps/fatigue. NCBI

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or “regenerative” drugs for CMT. The FDA warns that many marketed stem-cell/exosome products are unapproved and have caused serious harm. If anyone offers stem-cell injections for CMT outside a legitimate clinical trial, that is not FDA-approved therapy. The only FDA-approved stem-cell products are hematopoietic (cord-blood) cells for certain blood disorders—not for neuropathy. Please avoid clinics making broad claims. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

---

Surgeries

1. Tendon transfers (e.g., posterior tibial tendon transfer)
   Procedure: Re-routes a working tendon to lift the foot and correct foot-drop.
   Why: Improve toe clearance and reduce trips when AFO is insufficient. NCBI

2. Hammertoe correction
   Procedure: Straightens clawed toes (soft-tissue release and/or bony work).
   Why: Reduce shoe pain, calluses, and ulcers; improve push-off. NCBI

3. Cavovarus foot reconstruction
   Procedure: Combination of tendon balancing, plantar fascia release, calcaneal osteotomy.
   Why: Correct high-arch, inward-tilted heel deformity that destabilizes gait. NCBI

4. Achilles tendon lengthening
   Procedure: Lengthens tight heel cord limiting dorsiflexion.
   Why: Improve ankle motion and orthosis fit; lower forefoot pressure. NCBI

5. Ankle stabilization
   Procedure: Ligament repair or fusion in severe instability or painful arthritis.
   Why: Pain relief and safer walking when bracing fails. NCBI

---

Preventions

1. Avoid high-risk neurotoxic drugs where safe alternatives exist—especially vincristine; discuss risks with oncology teams if ever needed. Charcot-Marie-Tooth Association+1

2. Use AFOs/footwear to reduce falls and joint injuries. PMC

3. Daily stretching to delay contractures. PMC

4. Progressive exercise to prevent deconditioning. PubMed

5. Home safety: lights, rails, non-slip mats. PMC

6. Foot checks to catch blisters/sores early. NCBI

7. Vaccinations (e.g., flu/COVID) to avoid illness-related setbacks, per local guidance. NCBI

8. Plan breaks and manage fatigue in daily schedules. Charcot-Marie-Tooth Association

9. Maintain healthy weight to ease walking. NCBI

10. Join registries/trials via reputable CMT organizations. Scientia Salut

---

When to see a doctor

• New, rapidly worsening weakness, frequent trips/falls, or sudden foot-drop.

• Pain that prevents sleep or daily activities despite basic measures.

• Skin wounds, ulcers, or infections on feet (especially with numbness).

• Severe medication side-effects (e.g., mood changes on SNRIs/TCAs; swelling/sedation on gabapentinoids).

• Before cancer chemotherapy or other treatments that may be neurotoxic.

• Family planning or genetic counseling questions. NCBI+1

---

What to eat / what to avoid

What to eat:

• A balanced plate: lean protein (fish, poultry, legumes), vegetables, fruits, whole grains, and healthy fats (olive oil, nuts). Supports training response and weight management for easier walking.

• Sources of omega-3s (fish) and vitamin D (diet/sun within guidelines) as advised by your clinician.

• Adequate fluids and electrolytes around exercise to help cramps/fatigue. NCBI

What to avoid/limit:

• Ultra-processed, very high-sugar foods that worsen energy crashes and weight gain.

• Excess alcohol (can worsen neuropathy).

• Unproven “miracle” supplements or stem-cell/exosome therapies marketed outside trials. U.S. Food and Drug Administration+1

---

Frequently asked questions

1. Is there an approved cure for HARS1-CMT2W?
   No. Treatment is supportive; research is active. Scientia Salut

2. Will exercise make my nerves worse?
   With a therapist’s plan, progressive training helps function and doesn’t “use up” nerves. Overexertion is avoided. PubMed

3. Can braces really help?
   Yes—AFOs improve toe clearance and stability and can reduce falls and fatigue. PMC

4. Is pain from CMT purely nerve pain?
   Often mixed: burning/tingling (neuropathic) plus joint/soft-tissue pain from altered mechanics. Treatments may combine. NCBI

5. Are gabapentin or pregabalin approved for CMT?
   No—labels cover other neuropathic pains; CMT use is off-label, guided by your clinician. FDA Access Data

6. Is duloxetine useful?
   It’s approved for diabetic neuropathic pain; many clinicians try it off-label in CMT neuropathy. FDA Access Data

7. Do topical patches work?
   Lidocaine 5% and capsaicin 8% can help focal burning areas with low systemic risk. FDA Access Data+1

8. Should I take high-dose vitamins?
   Only to correct deficiencies; avoid chronic high-dose B6, which can itself cause neuropathy. NCBI

9. Can surgery fix the neuropathy?
   No, but it can correct foot deformities to improve function and comfort. NCBI

10. What about stem-cell clinics?
    Avoid them for CMT; FDA warns most marketed products are unapproved and risky. U.S. Food and Drug Administration

11. Is HARS1 always severe?
    Severity and age of onset vary widely—even within families. NCBI

12. Can children be affected?
    Yes; onset ranges from childhood to late adulthood. Genetic counseling helps families plan testing. NCBI

13. Are there medicines I should flag to doctors?
    Yes—vincristine and some other chemo drugs can be especially risky in CMT; always tell clinicians you have CMT before new treatments. Charcot-Marie-Tooth Association

14. How do orthoses get chosen?
    By a team (physiatry/PT/orthotist) after gait analysis; comfort and goals guide the device. Evidence supports use, but designs are individualized. The Foundation for Peripheral Neuropathy

15. Where can I find rehab guidance?
    The Charcot-Marie-Tooth Association and peer-reviewed rehab reviews provide practical, evidence-based advice. Charcot-Marie-Tooth Association+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 01, 2025.